ALD-ALLY is a call to action for advancing the science and care of patients with metabolic-dysfunction and alcohol-associated liver disease (MetALD and ALD)
Program Overview
IN-PERSON & VIRTUAL CONFERENCE
7.25 ACCME CREDITS
We’re excited to announce the 2nd annual ALD-ALLY (Alcohol-associated Liver Disease patients deserve ALcohol LiteracY) Conference, scheduled on April 10, 2026.
This one-day CME conference is designed to meet the educational needs of healthcare professionals. It will facilitate intimate dialogues among experts, providers, and stakeholders, aiming to enhance collaboration, advocacy, research, and care delivery for patients with Alcohol-Associated Liver Disease (ALD). Our goal is to foster meaningful discussions that will advance the field of ALD and MetALD.
The conference will kick off on Friday morning, with the exhibits open from breakfast until the conclusion of the evening reception. A light reception will take place in the exhibit hall immediately following the last presentation. All breaks will be held in the exhibit hall to encourage attendee engagement and foot traffic throughout the space. ALD-ALLY is a call to action for advancing the science and care of patients with alcohol-associated liver disease (ALD) by gathering international experts to lead a multidisciplinary dialogue among a wide spectrum of stakeholders. Our intent is for ALD-ALLY to become the premier annual ALD meeting focused on actionable initiatives and collaborations through state-of-the-art lectures, academic debates, and patient advocacy in a lively in-person, discussion-encouraged setting. Be an ALLY and join us in New York!
NOTE: In-person registration includes light breakfast, lunch and reception
NOTE: Q&A sessions are reserved for in-person attendees only
Learning Objectives- Explore the details of high impact, practice-changing studies in MetLAD, ALD and AUD.
- Discuss emerging concepts and future therapeutics in MetALD.
- Identify how genetics and biomarkers can guide personalized treatment plans for patients with Metabolic and Alcohol-associated Liver Diseases.
- Explore the application and impact of digital tools, such as wearables and remote monitoring, in enhancing the management of alochol-related health issues.
- Distinguish between fact and fiction regarding contraindications in medications for AUD in paitents with advanced MetALD or ALD.
- Target successful models of integrating care across inpatient and outpatient settings, emphasizing coordination and mulitdisciplinary collaboration.
- Discuss and understand the importance of integrating patient voices and experiences into the decision-making process to improve treatment adherence and outcomes.
Agenda Highlights- Emerging Concepts and Therapies for MetALD
- Advances in Digital Care for ALD and MetALD
- Incorporating Genetics and Biomarkers in MASH, MetALD, and ALD Care
- High Impact Studies in AUD, ALD, and MetALD— Year in Review
- Innovations in Integrated Alcohol Care: Inpatient, Outpatient, and the Patient Voice
- Alcohol and MetALD Debates
Video Access
Following the program, all registrants will have access to lecture video recordings for ONE month.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Columbia University. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Professions in scope for this activity are listed below. Amedco Joint Accreditation #4008163.
Physicians
Amedco LLC designates this live virtual activity for a maximum of 7.25 AMA PRA Category 1 Credits™ for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.
Physician Assistants
The National Commission on Certification of Physician Assistant (NCCPA) states that AMA PRA Category 1 Credit™ are acceptable for continuing medical education requirements for recertification for PAs. Amedco LLC designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credit™. PAs should claim only the credit commensurate with the extent of their participation in the activity.
